NAICS 541714: Research and Development in Biotechnology
This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development.  Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials.  This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.

Illustrative Examples:

Cloning research and experimental development laboratories 
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories 

ExioML sector: Research and development services (73)
Region: US | Year: 2022
Sector value added: 101689.895384 M EUR | Employment: 9284.95382206 thousand persons
Sector GHG emissions: 1501417868.95 kg CO2 eq | Energy carrier net total: 142153.6007 TJ | Carbon intensity: 0.014764671192554249

Company: PRA Health Sciences Inc
PRA Health Sciences, Inc. is a global contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries.